As May begins, there are no signs of a let-up in Peru’s sufferings from Covid-19. April saw the highest number of deaths since the pandemic first broke, according to figures released at the end of last week by the National Epidemiological Centre (attached to the Ministry of Health).

The official death figures for the month show a 50% rise on those for March. 8,255 people lost their lives to Covid in April compared with 5,476 in March. As we have made clear in previous newsletters, the death rate is probably much higher than the official figures suggest. The death toll was well above 400 a day in mid-April.

Altogether, the official figures point to 1.78 million cases being registered since the pandemic began, with over 60,000 people having lost their lives.

The health system still labours under enormous stress. Of a total of 2,202 intensive care beds nationwide, 97.5% were occupied as April ended. Reports from Arequipa tell of patients being turned away from hospital. In Piura, ten people await unattended for every hospital bed to come available. The only part of Peru where numbers of people infected appears to be declining is in Loreto region.

The appearance of a new ‘Peruvian’ variant, known as C.37, seems to be helping raise the number of cases, although health officials remain uncertain as to its precise nature. In recent weeks, the numbers of relatively younger people infected has increased notably. However, it is unclear whether this is due more to the inability to maintain rules regarding social distancing among younger people.

On 28 April, Peru received 200,000 doses of the Pfizer/BioNTech which will help speed up the country’s tardy vaccination programme. This coming week, vaccination will begin in the Lima Callao area for those between the ages of 70 and 79. The target is to administer 25,000 doses a day.

The government hopes that a further 1.8 million doses will arrive in May. According to President Francisco Sagasti, Peru should also receive 500,000 doses of the Astra Zeneca vaccine through the Covax Facility. So far, only 2% of the population have received two doses.

The Ombudsman’s Office (Defensoría del Pueblo) has appealed to the government to be more transparent in its timetable for the distribution of doses across the country, adding its voice to that of the association of regional governors.

Distribution of the Pfizer BioNTech vaccine is likely to be restricted by the lack of facilities outside major cities to keep it at the very low temperatures required for it to be efficacious.

The speed at which the vaccination programme progresses will determine whether or not there will be a let-up in the present lock-down regulations. These will be reassessed on 10 May. It will also have a material bearing on whether Sagasti reaches the end of his allotted term of office with much credibility.